Partnership Will Aid Physicians in Precision Prescribing Decisions Based on Applied DNA's TR8™ Pharmacogenomic (PGx) Test STONY BROOK, NY /…
Global leader in personalized predictive genetics launches testing operations for geneType disease risk assessments at US based, world-leading genetic laboratory,…
STONY BROOK, NY / ACCESSWIRE / June 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),…
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancerSALT LAKE CITY, June 11, 2024…
Patent covers the Composition of the Company's Proprietary Linea™ RNAP, a Core Technology Empowering the Linea™ IVT PlatformPatent Application Also…
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader…
STONY BROOK, NY / ACCESSWIRE / May 28, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),…
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and CollaboratorsSALT…
PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GeneType”), a global leader…
STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in…